GlassScriptPhysician profile
Ghislaine Tonye
NPI 1679160949
$1,567.74
in general payments reported to CMS, 2019-2025
19 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $29.46 · 2023: $288 · 2024: $483 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $241.30 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $234.00 | 2023-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $169.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.26 | 2021-2024 | Trintellix |
| Abbvie INC. | $112.96 | 2022-2025 | |
| Tempus Ai, INC | $112.39 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.54 | 2021-2025 | Caplyta |
| Corium, LLC | $93.13 | 2025 | Azstarys |
| Cequr Corporation | $88.34 | 2025 | Cequr Simplicity |
| Teva Pharmaceuticals USA, INC. | $63.34 | 2021-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $51.53 | 2024-2025 | Auvelity |
| Indivior INC. | $40.61 | 2023 | Perseris |
| Eisai INC. | $34.22 | 2021 | |
| Madrigal Pharmaceuticals | $26.73 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $18.89 | 2023 | |
| Mannkind Corporation | $18.10 | 2025 | |
| Lundbeck LLC | $14.15 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $13.45 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghislaine Tonye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.